Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis.

Détails

ID Serval
serval:BIB_CD0B11237101
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis.
Périodique
Clinical neurology and neurosurgery
Auteur(s)
Treglia G., Stefanelli A., Cason E., Cocciolillo F., Di Giuda D., Giordano A.
ISSN
1872-6968 (Electronic)
ISSN-L
0303-8467
Statut éditorial
Publié
Date de publication
12/2011
Peer-reviewed
Oui
Volume
113
Numéro
10
Pages
823-829
Langue
anglais
Notes
Publication types: Journal Article ; Meta-Analysis ; Review
Publication Status: ppublish
Résumé
This study was designed to review the diagnostic performance of iodine-123-metaiodobenzylguanidine (MIBG) scintigraphy in differential diagnosis between Parkinson's disease (PD) and multiple-system atrophy (MSA).
A comprehensive computer literature search of studies published through March 2011 regarding MIBG scintigraphy in patients with PD and MSA was performed in PubMed/MEDLINE and Embase databases. Only studies in which MIBG scintigraphy was performed for differential diagnosis between PD and MSA were selected. Pooled sensitivity and specificity of MIBG scintigraphy were presented with a 95% confidence interval (CI). The area under the ROC curve was calculated to measure the accuracy of MIBG scintigraphy in differential diagnosis between PD and MSA.
Ultimately, we identified 12 studies comprising a total of 1226 patients (593 patients with PD, 117 patients with other Lewy body disease, 129 patients with MSA, and 387 patients with other diseases). The pooled sensitivity of MIBG scintigraphy to detect PD was 89% (95% CI: 86-91%); the pooled specificity of MIBG scintigraphy to discriminate between PD and MSA was 77% (95% CI: 68-84%). The area under the ROC curve was 0.93.
MIBG scintigraphy is an accurate test for PD detection and differential diagnosis between PD and MSA; this method shows high sensitivity and adequate specificity in this field. Nevertheless, possible causes of false negative and false positive findings should be considered when interpreting the scintigraphic results.

Mots-clé
3-Iodobenzylguanidine, Confidence Intervals, Data Interpretation, Statistical, Diagnosis, Differential, Humans, Image Processing, Computer-Assisted, Multiple System Atrophy/diagnosis, Multiple System Atrophy/diagnostic imaging, Parkinson Disease/diagnosis, Parkinson Disease/diagnostic imaging, ROC Curve, Radiopharmaceuticals, Reproducibility of Results, Tomography, Emission-Computed, Single-Photon
Pubmed
Web of science
Création de la notice
20/08/2017 22:13
Dernière modification de la notice
20/08/2019 16:47
Données d'usage